search
Back to results

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
placebo
telmisartan + HCTZ
telmisartan + HCTZ
amlodipine
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean seated systolic blood pressure (SBP) must be =<200 mmHg
  2. Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion
  3. Age 20 years or older

Exclusion criteria:

  1. Patients with known or suspected secondary hypertension
  2. Patients with clinically relevant cardiac arrhythmia
  3. Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
  4. Patients with recent cardiovascular events
  5. Patients with recent stroke events
  6. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy
  7. Patients with hepatic and/or renal dysfunction
  8. Pre-menopausal women who are nursing or pregnant

Sites / Locations

  • 1348.2.020 Boehringer Ingelheim Investigational Site
  • 1348.2.008 Boehringer Ingelheim Investigational Site
  • 1348.2.018 Boehringer Ingelheim Investigational Site
  • 1348.2.006 Boehringer Ingelheim Investigational Site
  • 1348.2.013 Boehringer Ingelheim Investigational Site
  • 1348.2.021 Boehringer Ingelheim Investigational Site
  • 1348.2.012 Boehringer Ingelheim Investigational Site
  • 1348.2.011 Boehringer Ingelheim Investigational Site
  • 1348.2.001 Boehringer Ingelheim Investigational Site
  • 1348.2.019 Boehringer Ingelheim Investigational Site
  • 1348.2.014 Boehringer Ingelheim Investigational Site
  • 1348.2.002 Boehringer Ingelheim Investigational Site
  • 1348.2.007 Boehringer Ingelheim Investigational Site
  • 1348.2.009 Boehringer Ingelheim Investigational Site
  • 1348.2.005 Boehringer Ingelheim Investigational Site
  • 1348.2.016 Boehringer Ingelheim Investigational Site
  • 1348.2.010 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

telmisartan + HCTZ + amlodipine

telmisartan + HCTZ + placebo

Arm Description

telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)

telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)

Outcomes

Primary Outcome Measures

Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Secondary Outcome Measures

Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.
The percentage of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.
The number of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.
Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.
Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Full Information

First Posted
July 26, 2013
Last Updated
February 26, 2016
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT01911780
Brief Title
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
Official Title
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg. Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/H12.5 mg. In addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide 12.5 mg will be evaluated in a 52-week extension period. In the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5 mg group change to the T80/A5/H12.5 mg therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
132 (Actual)

8. Arms, Groups, and Interventions

Arm Title
telmisartan + HCTZ + amlodipine
Arm Type
Experimental
Arm Description
telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
Arm Title
telmisartan + HCTZ + placebo
Arm Type
Active Comparator
Arm Description
telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo matching amlodipine capsule
Intervention Type
Drug
Intervention Name(s)
telmisartan + HCTZ
Intervention Description
FDC tablet
Intervention Type
Drug
Intervention Name(s)
telmisartan + HCTZ
Intervention Description
FDC tablet
Intervention Type
Drug
Intervention Name(s)
amlodipine
Intervention Description
capsule
Primary Outcome Measure Information:
Title
Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
Description
Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time Frame
baseline and 8 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
Description
Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time Frame
baseline and 8 weeks
Title
The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.
Description
The percentage of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time Frame
Double-blind and 8 weeks
Title
The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.
Description
The number of patients with DBP<90 mmHg and SBP<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time Frame
Reference baseline (week 0) and week 60 (end of extension period)
Title
Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.
Description
Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time Frame
Reference baseline (week 0) and week 60 (end of extension period)
Title
Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.
Description
Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time Frame
Reference baseline (week 0) and week 60 (end of extension period)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be >=90 and <=114 mmHg and mean seated systolic blood pressure (SBP) must be =<200 mmHg Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion Age 20 years or older Exclusion criteria: Patients with known or suspected secondary hypertension Patients with clinically relevant cardiac arrhythmia Congestive heart failure with New York Heart Association (NYHA) functional class III-IV Patients with recent cardiovascular events Patients with recent stroke events Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy Patients with hepatic and/or renal dysfunction Pre-menopausal women who are nursing or pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1348.2.020 Boehringer Ingelheim Investigational Site
City
Chiyoda-ku, Tokyo
Country
Japan
Facility Name
1348.2.008 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Fukuoka, Fukuoka
Country
Japan
Facility Name
1348.2.018 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Kobe, Hyogo
Country
Japan
Facility Name
1348.2.006 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Tokyo
Country
Japan
Facility Name
1348.2.013 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Tokyo
Country
Japan
Facility Name
1348.2.021 Boehringer Ingelheim Investigational Site
City
Chuo-ku,Tokyo
Country
Japan
Facility Name
1348.2.012 Boehringer Ingelheim Investigational Site
City
Hirakata, Osaka
Country
Japan
Facility Name
1348.2.011 Boehringer Ingelheim Investigational Site
City
Kasaoka, Okayama
Country
Japan
Facility Name
1348.2.001 Boehringer Ingelheim Investigational Site
City
Kawasaki, Kanagawa
Country
Japan
Facility Name
1348.2.019 Boehringer Ingelheim Investigational Site
City
Kita-ku, Osaka-shi, Osaka
Country
Japan
Facility Name
1348.2.014 Boehringer Ingelheim Investigational Site
City
Kiyota-ku, Sapporo-shi, Hokkaido
Country
Japan
Facility Name
1348.2.002 Boehringer Ingelheim Investigational Site
City
Kumamoto, Kumamoto
Country
Japan
Facility Name
1348.2.007 Boehringer Ingelheim Investigational Site
City
Nakano-ku,Tokyo
Country
Japan
Facility Name
1348.2.009 Boehringer Ingelheim Investigational Site
City
Nishi-ku, Fukuoka, Fukuoka
Country
Japan
Facility Name
1348.2.005 Boehringer Ingelheim Investigational Site
City
Takatsuki, Osaka
Country
Japan
Facility Name
1348.2.016 Boehringer Ingelheim Investigational Site
City
Uji, Kyoto
Country
Japan
Facility Name
1348.2.010 Boehringer Ingelheim Investigational Site
City
Yoshikawa, Saitama
Country
Japan

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info

Learn more about this trial

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

We'll reach out to this number within 24 hrs